Published in Neuropsychiatr Dis Treat on April 08, 2009
Update in restless legs syndrome. Curr Opin Neurol (2010) 0.92
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med (2003) 12.71
Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med (2007) 6.23
Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med (2007) 5.95
A genetic risk factor for periodic limb movements in sleep. N Engl J Med (2007) 5.77
Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med (2005) 4.97
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54
Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med (2004) 3.49
Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord (1997) 2.67
Recording and scoring leg movements. The Atlas Task Force. Sleep (1993) 2.62
Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology (2008) 2.28
The role of iron in restless legs syndrome. Mov Disord (2007) 2.14
Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology (2003) 2.04
Therapy in restless legs. Acta Med Scand (1953) 2.00
Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology (2006) 1.99
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78
MRI measurement of brain iron in patients with restless legs syndrome. Neurology (2001) 1.75
Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med (2005) 1.60
Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med (2006) 1.58
Charcot-Marie-Tooth disease type 2 with restless legs syndrome. Neurology (1999) 1.55
Subclinical sensory neuropathy in late-onset restless legs syndrome. Neurology (2000) 1.45
Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci? Neurology (2007) 1.42
Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep (2007) 1.41
Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep (2000) 1.37
An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep (2004) 1.34
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord (2008) 1.33
"Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol (2005) 1.31
Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet (2001) 1.30
Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain (2003) 1.29
Seeing speech affects acoustic information processing in the human brainstem. Exp Brain Res (2005) 1.23
Projections of diencephalic dopamine neurons into the spinal cord in mice. Exp Brain Res (2005) 1.22
Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord (1998) 1.22
Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep (2008) 1.22
Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol (2005) 1.22
Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord (2007) 1.21
Burden of restless legs syndrome on health-related quality of life. Qual Life Res (2007) 1.21
Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet (2004) 1.18
The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep (1999) 1.17
A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis (2004) 1.15
Arm restlessness as the initial symptom in restless legs syndrome. Arch Neurol (2003) 1.15
The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med (2004) 1.14
Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol (2007) 1.14
Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord (2000) 1.12
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med (2007) 1.06
Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep (2004) 1.05
Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord (1999) 1.05
Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet (2006) 1.03
Periodic arm movements in patients with the restless legs syndrome. Eur Neurol (2000) 1.03
Effects of periodic leg movements during sleep in middle-aged subjects without sleep complaints. Mov Disord (2005) 1.02
Evidence of peripheral axonal neuropathy in primary restless legs syndrome. Mov Disord (1995) 1.02
Arm restlessness in patients with restless legs syndrome. Mov Disord (2000) 1.01
Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord (2004) 1.00
Restless arms. Lancet (2008) 0.99
A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med (2008) 0.99
Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov Disord (2007) 0.99
State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord (2007) 0.98
Restless legs syndrome in diabetic neuropathy: a frequent manifestation of small fiber neuropathy. J Peripher Nerv Syst (2007) 0.98
Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol (2005) 0.98
Treatment wish of individuals with known and unknown restless legs syndrome in the community. J Neurol (2008) 0.97
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol (1999) 0.97
A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology (2006) 0.97
Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep (1999) 0.96
Effects of immobility on sensory and motor symptoms of restless legs syndrome. Mov Disord (2002) 0.95
Validation of the "L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord (2006) 0.93
Restless legs syndrome in patients with polyneuropathy. Muscle Nerve (1996) 0.93
Evidence for further genetic locus heterogeneity and confirmation of RLS-1 in restless legs syndrome. Mov Disord (2006) 0.90
The 14q restless legs syndrome locus in the French Canadian population. Ann Neurol (2004) 0.89
The clinical neurophysiology of the restless legs syndrome and periodic limb movements. Part I: diagnosis, assessment, and characterization. Clin Neurophysiol (2004) 0.88
Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics (2008) 0.88
One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med (2008) 0.88
Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep (1996) 0.88
Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol (2004) 0.87
Genetics of restless legs syndrome. Curr Neurol Neurosci Rep (2008) 0.87
EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol (2006) 0.87
Dopaminergic effects on tail-flick response in spinal rats. Eur J Pharmacol (1982) 0.86
Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry (2002) 0.85
A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep (1991) 0.85
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord (2007) 0.85
The effects of dietary iron deprivation on murine circadian sleep architecture. Sleep Med (2006) 0.84
RLS3: fine-mapping of an autosomal dominant locus in a family with intrafamilial heterogeneity. Neurology (2006) 0.84
Assessment of restless legs syndrome--methodological approaches for use in practice and clinical trials. Mov Disord (2007) 0.84
Letter: Restless arms syndrome. JAMA (1976) 0.81
Clozapine-associated restless legs syndrome. J Clin Psychopharmacol (2007) 0.80
Endocrine rhythms in patients with restless legs syndrome. J Neurol (2002) 0.80
Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol (2005) 0.80
Restless legs syndrome: diagnosis, epidemiology, classification and consequences. Neurol Sci (2007) 0.80
Circadian variation in restless legs syndrome. Sleep Med (2007) 0.79
Restless legs syndrome and peripheral neuropathy. J Neurol Neurosurg Psychiatry (2002) 0.79
Iron deficiency induces reversal of dopamine dependent circadian cycles: differential response to d-amphetamine and TRH. Peptides (1986) 0.79
Circadian variation of the effects of immobility on symptoms of restless legs syndrome. Sleep (2005) 0.79
Pergolide-associated 'sleep attacks' in a patient with restless legs syndrome. Sleep Med (2002) 0.78
Restless legs syndrome and nocturnal myoclonus: initial clinical manifestation of familial amyloid polyneuropathy. J Neurol Neurosurg Psychiatry (1990) 0.78
Cryoglobulinaemic neuropathy manifesting with restless legs syndrome. J Neurol Sci (1997) 0.78
Restless legs syndrome (RLS) with expansion of symptoms to the face. Sleep Med (2007) 0.77
Urinary 6-hydroxy-melatonin-sulfate excretion and circadian rhythm in patients with restless legs syndrome. J Pineal Res (2003) 0.76
Dopaminergic receptors in cat brain. Action of triton X-100 on [3H]spiroperidol binding and localization in relation to the synaptic region. Eur J Pharmacol (1982) 0.75
Restless arm symptoms as an extension of restless leg syndrome. Age Ageing (2006) 0.75
Sleep disorders in patients with end-stage renal disease undergoing dialysis therapy. Nephrol Dial Transplant (2005) 2.12
The accuracy of discharge diagnosis coding for Amyotrophic Lateral Sclerosis in a large teaching hospital. Eur J Epidemiol (2009) 1.67
Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study. J Clin Psychopharmacol (2008) 1.54
Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep (2007) 1.41
Restless legs syndrome in end-stage renal disease. Sleep Med (2004) 1.35
Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep (2008) 1.22
Letter by D'Anna et al regarding article, "Long-term mortality in patients with stroke of undetermined etiology". Stroke (2012) 1.06
Consensus on diagnosis and management of JME: From founder's observations to current trends. Epilepsy Behav (2013) 1.01
Specific impairments of rule induction in different frontal lobe subgroups. Neuropsychologia (2005) 0.97
Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci (2009) 0.95
Incidence of transient ischemic attack and early stroke risk: validation of the ABCD2 score in an Italian population-based study. Stroke (2011) 0.95
Changes of cortical excitability after dopaminergic treatment in restless legs syndrome. Sleep Med (2010) 0.88
Degraded semantic knowledge and accurate object use. Cortex (2007) 0.87
A case-control study on restless legs syndrome in nondialyzed patients with chronic renal failure. Mov Disord (2010) 0.86
Epidemiology and clinical features of sleep disorders in extrapyramidal disease. Sleep Med (2004) 0.86
Increasing cortical excitability: a possible explanation for the proconvulsant role of sleep deprivation. Sleep (2006) 0.85
Sleep disturbances in dialysis patients. J Nephrol (2008) 0.84
Effects of restless legs syndrome on quality of life and psychological status in patients with type 2 diabetes. Diabetes Educ (2010) 0.83
Sleep before and after temporal lobe epilepsy surgery. Seizure (2012) 0.82
Nerve fibre layer analysis with GDx with a variable corneal compensator in patients with multiple sclerosis. Ophthalmologica (2007) 0.82
Stroke incidence and 30-day and six-month case fatality rates in Udine, Italy: a population-based prospective study. Int J Stroke (2013) 0.81
Tickborne encephalitis virus, northeastern Italy. Emerg Infect Dis (2006) 0.81
Focal epilepsy as first symptom in CADASIL. Seizure (2011) 0.81
Restless legs syndrome in dialysis patients: a comparison between hemodialysis and continuous ambulatory peritoneal dialysis. Neurol Sci (2012) 0.80
Absence of postexercise and delayed facilitation of motor cortex excitability in restless legs syndrome: evidence of altered cortical plasticity? Sleep (2006) 0.80
Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease. J Clin Neurophysiol (2006) 0.80
Association of body rolling, leg rolling, and rhythmic feet movements in a young adult: A video-polysomnographic study performed before and after one night of clonazepam. Mov Disord (2008) 0.80
Neurophysiology of juvenile myoclonic epilepsy. Epilepsy Behav (2013) 0.80
Wake-up stroke and TIA due to paradoxical embolism during long obstructive sleep apnoeas: a cross-sectional study. Thorax (2012) 0.80
Lacosamide for the treatment of epilepsy. Expert Opin Drug Metab Toxicol (2014) 0.79
Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease? Expert Opin Drug Saf (2009) 0.79
Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome. Curr Opin Investig Drugs (2009) 0.79
Sarcoidosis as risk factor for cryptococcal meningitis in an apparently immunocompetent patient. Neurol Sci (2008) 0.79
Polysomnographic Sleep Patterns in Children and Adolescents in Unresponsive Wakefulness Syndrome. J Head Trauma Rehabil (2015) 0.78
Worsening of negative myoclonus by lamotrigine in a case of idiopathic focal epilepsy of children with long-term follow-up. Brain Dev (2011) 0.77
The withdrawal of nutrition and hydration in the vegetative state patient: societal dimension and issues at stake for the medical profession. NeuroRehabilitation (2004) 0.77
Gabapentin enacarbil in restless legs syndrome. Drugs Today (Barc) (2010) 0.77
The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial. Neuropsychobiology (2007) 0.77
Motor cortex excitability in restless legs syndrome. Sleep Med (2004) 0.77
Are Early Seizures Predictive of Epilepsy after a Stroke? Results of a Population-Based Study. Neuroepidemiology (2015) 0.77
Varenicline-induced grand mal seizure. Epileptic Disord (2010) 0.77
Clinical experience with pramipexole in the treatment of restless legs syndrome. Expert Opin Drug Metab Toxicol (2008) 0.76
Temporal intermittent δ activity: a marker of juvenile absence epilepsy? Seizure (2010) 0.76
ADMET considerations for restless leg syndrome drug treatments. Expert Opin Drug Metab Toxicol (2012) 0.76
Response to restless legs syndrome and diabetic neuropathy--commentary by Gemignani, et al. Sleep (2008) 0.76
Seizures with prolonged EEG abnormalities during an attack of migraine without aura. Headache (2007) 0.76
The use of rotigotine in the treatment of restless legs syndrome. Ther Adv Neurol Disord (2010) 0.75
Sleep-related movement disorders. Neurol Sci (2011) 0.75
Investigational approaches to therapies for restless legs syndrome. Expert Opin Investig Drugs (2014) 0.75
The unfinished project: ethical problems and strategies for action on mental retardation. Dolentium Hominum (1997) 0.75
Considerations on the scientific and ethical problems related to vegetative state. Med Etika Bioet (2005) 0.75
Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients. Neurodegener Dis (2017) 0.75
The promise of the Catholic doctor: a proposal of the Executive Committee of FIAMC. Decisions (1998) 0.75
Panic disorder or epilepsy? A case report. J Neurol Sci (2006) 0.75
Genetic heterogeneity in inherited spastic paraplegia associated with epilepsy. Am J Med Genet A (2003) 0.75
Insomnia in general practice : a consensus report produced by sleep specialists and primary-care physicians in Italy. Clin Drug Investig (2005) 0.75
Foreword. NeuroRehabilitation (2004) 0.75
ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome. Expert Opin Drug Metab Toxicol (2014) 0.75
Statement on euthanasia in children. Med Etika Bioet (2005) 0.75
A new approach for the detection of the fourteen- and six-Hertz positive bursts (6-14 Hz): the lower temporal line. Clin Neurophysiol (2010) 0.75
Video-EEG in syncopal attack due to ocular compression in an adolescent mistreated for epilepsy. Epileptic Disord (2007) 0.75